Skip to main content

Advertisement

Table 1 Comparison of clinical and molecular characteristics of de novo AML patients according to ETS2

From: High expression of ETS2 predicts poor prognosis in acute myeloid leukemia and may guide treatment decisions

Variable AML (TCGA dataset)
ETS2high (n = 89) ETS2low (n = 90) P
Median age, year (range)    0.01
 Median 61 54.5  
 Range (18–88) (22–82)  
Age group, n (%)    0.004
 <60 38 58  
 ≥60 51 32  
WBC count, X109/L    0.05
 Median 33.2 12.2  
 Range 0.6–297.4 0.4–202.7  
BM blasts (%)    0.6
 Median 74 72  
 Range 32–100 30–100  
PB blasts (%)    0.01
 Median 49 25  
 Range 0–98 0–97  
FAB subtype, no (%)    
 M0 14 2 0.001
 M1 30 14 0.005
 M2 18 22 0.59
 M3 0 16 <0.001
 M4 16 19 0.6
 M5 6 15 0.04
 M6 1 1 1
 Others 4 1 0.21
FLT3-ITD, n (%)    0.01
 Present 25 12  
 Absent 64 78  
NPM1 (no FLT3-ITD), n (%)    0.33
 Mutated 12 17  
 Wild-type 77 73  
CEBPA, n (%)    0.24
 Single mutated 3 5  
 Double mutated 1 4  
 Wild-type 85 81  
MLL-PTD, n (%)    0.33
 Mutated 6 3  
 Wild-type 83 87  
IDH1, n (%)    0.58
 Mutated 9 7  
 Wild-type 80 83  
IDH2, n (%)    0.78
 Mutated 9 8  
 Wild-type 80 82  
RUNX1, n (%)    0.08
 Mutated 12 5  
 Wild-type 77 85  
DNMT3A, n (%)    0.21
 R882 mutated 16 7  
 Non-R822 mutated 9 11  
 Wild-type 64 72  
TP53, n (%)    0.016
 Mutated 12 3  
 Wild-type 77 87  
ERG expression, n (%)    0.16
 High 49 40  
 Low 40 50  
BAALC expression, n (%)    0.07
 High 50 39  
 Low 39 51  
MN1 expression, n (%)    0.04
 High 51 38  
 Low 38 52  
miR155HG expression, n (%)    <0.001
 High 56 33  
 Low 33 57  
WT1 expression, n (%)    0.009
 High 53 36  
 Low 36 54  
  1. High ERG, BAALC, MN1, miR155HG and WT1 expression were defined as an expression level above the median of all samples, respectively
  2. FAB French–American–British classification, FLT3-ITD internal tandem duplication of the FLT3 gene, MLL-PTD partial tandem duplication of the MLL gene